At 6.6% CAGR, South & Central America Hyperpigmentation Disorder Treatment Market is Projected to be worth US$ 1,484.28 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the South & Central America hyperpigmentation disorder treatment market was valued at US$ 887.76 million in 2022 and is expected to reach US$ 1,484.28 million by 2030, registering a CAGR of 6.6% from 2022 to 2030. Use of ablative lasers and rise in prevalence of melasma are among the critical factors attributed to drive the South & Central America hyperpigmentation disorder treatment market growth.

There have been many advancements in laser devices designed to treat hyperpigmentation. Ablative lasers such as Erbium:YAG (Er:YAG) and carbon dioxide (CO2) have been in use to treat acne scars. Nevertheless, side effects led to a decrease in the popularity of this technique. Subsequently, nonablative lasers such as NdYAG lasers and erbium glass gained traction in the treatment of hyperpigmentation. Although this technique has less risk, it is not a reliable one due to the inadequacy of results. With advancements in fractional technology, treating hyperpigmentation with ablative lasers such as CO2 and erbium YAG has regained popularity. Thus, using ablative lasers such as CO2 and Er:YAG for hyperpigmentation treatment is expected to bring new hyperpigmentation disorder treatment market trends during the forecast period.

On the contrary, high cost of treatments hampers the growth of South & Central America hyperpigmentation disorder treatment market.

By treatment type, the South & Central America hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held 42.7% share of South & Central America hyperpigmentation disorder treatment market share in 2022, amassing US$ 379.31 million. It is projected to garner US$ 657.37 million by 2031 to register 7.1% CAGR during 2022–2030

In terms of condition, the South & Central America hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held 47.1% share of South & Central America hyperpigmentation disorder treatment market share in 2022, amassing US$ 418.16 million. It is projected to garner US$ 717.71 million by 2031 to register 7.0% CAGR during 2022–2030

Based on end user, the South & Central America hyperpigmentation disorder treatment market is hospitals, dermatology centers, and others. The hospital segment held 48.2% share of South & Central America hyperpigmentation disorder treatment market share in 2022, amassing US$ 427.86 million. It is projected to garner US$ 710.57 million by 2031 to register 6.5% CAGR during 2022–2030

Based on country, the South & Central America hyperpigmentation disorder treatment market is categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 49.3% share of South & Central America hyperpigmentation disorder treatment market in 2022. It was assessed at US$ 437.26 million in 2022 and is likely to hit US$ 751.85 million by 2030, registering a CAGR of 7.0% during 2022–2030

Key players operating in the South & Central America hyperpigmentation disorder treatment market are AbbVie Inc, Bayer AG, Galderma SA, L’OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA, among others.

• In February 2024: L'Oréal Paris launched the Glycolic Bright Dark Circle Eye Serum, a groundbreaking solution for under-eye hyperpigmentation and puffiness. The serum, formulated with a blend of 3 percent Glycolic Acid, Vitamin CG, and Niacinamide, promises to diminish dark circles by -49% in just two weeks. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com